PB2178: OUTCOMES OF REDUCED DOSE TEAM (THIOTEPA, ETOPOSIDE, CYTARABINE, MELPHALAN) PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANTATION FOR HODGKIN AND NON-HODGKIN LYMPHOMA: A MONOCENTRIC EXPERIENCE

Podobne knjige/članki

• Clinical and safety outcomes of BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) versus CEM (Carboplatin, Etoposide, Melphalan) in lymphoma patients as a conditioning regimen before autologous hematopoietic cell transplantation
  od: Mohamed A. Eltelbanei, et al.
  Izdano: (2024-08-01)
• Evaluating the Efficacy of Modified BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) Regimen as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Lymphoma: An Experience from Two Centers of a Developing Country
  od: Mani Ramzi, et al.
  Izdano: (2023-04-01)
• PB2178: OUTCOMES OF REDUCED DOSE TEAM (THIOTEPA, ETOPOSIDE, CYTARABINE, MELPHALAN) PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANTATION FOR HODGKIN AND NON-HODGKIN LYMPHOMA: A MONOCENTRIC EXPERIENCE
  od: S. Di Folca, et al.
  Izdano: (2022-06-01)
• The Efficacy and Safety of Busulfan-Etoposide-Melphalan Regimen in Autologous Stem Cell Transplantation in Relapsed/ Refractory Hodgkin and Non-Hodgkin Lymphoma Patients: “A Single-Center Experience”
  od: Ali Eser, et al.
  Izdano: (2021-05-01)
• Preventing Thrombosis in Cancer Patients
  od: Budi Setiawan, et al.
  Izdano: (2023-01-01)